secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001213900-24-095175
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS
--------------------------------------------------------------------------------

- Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.
- SPOTLIGHT study: 93% clinical response (83% complete response) in 120mg cohort; no SAEs.
- Initial BEACON data in CSU expected week of Jan 6, 2025; asthma challenge study cleared in Canada/EU.
- Discontinued LR-MDS program as briquilimab did not improve hematopoiesis.
- R&D expenses $14.5M, G&A $5.4M for Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024095175/0001213900-24-095175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024095175/ea0220162-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-095175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer